Latest filings (excl ownership)
8-K
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
15 May 24
10-Q
2024 Q1
Quarterly report
14 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
RW
Registration withdrawal request
17 Apr 24
FWP
Free writing prospectus
2 Apr 24
S-1/A
IPO registration (amended)
29 Mar 24
8-K
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
18 Mar 24
S-1
IPO registration
18 Mar 24
S-8
Registration of securities for employees
15 Mar 24
10-K
2023 FY
Annual report
15 Mar 24
8-K
Entry into a Material Definitive Agreement
15 Nov 23
424B5
Prospectus supplement for primary offering
15 Nov 23
8-K
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
14 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
3 Nov 23
8-K
Other Events
2 Oct 23
8-K
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
14 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
424B3
Prospectus supplement
13 Jul 23
EFFECT
Notice of effectiveness
11 Jul 23
CORRESP
Correspondence with SEC
6 Jul 23
UPLOAD
Letter from SEC
5 Jul 23
S-1
IPO registration
29 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
20 Jun 23
424B3
Prospectus supplement
18 May 23
424B5
Prospectus supplement for primary offering
17 May 23
8-K
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering
17 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
PRE 14A
Preliminary proxy
17 Apr 23
8-K
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
16 Mar 23
S-8
Registration of securities for employees
15 Mar 23
10-K
2022 FY
Annual report
15 Mar 23
8-K
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update
14 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
424B3
Prospectus supplement
23 Sep 22
Latest ownership filings
4
DAVID P LUCI
3 Apr 24
4
Robert G. Shawah
3 Apr 24
4
ROBERT J DELUCCIA
3 Apr 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Carl Sailer
22 Jan 24
4
ROBERT J DELUCCIA
4 Jan 24
4
DAVID P LUCI
4 Jan 24
4
James J. Donohue
16 Jun 23
4
THOMAS L HARRISON
16 Jun 23
4
JACK H DEAN
16 Jun 23
4
Carl Sailer
16 Jun 23
4
Joseph C Scodari
16 Jun 23
4
Robert G. Shawah
24 Feb 23
4
DAVID P LUCI
24 Feb 23
4
ROBERT J DELUCCIA
24 Feb 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
4
Carl Sailer
29 Jul 22
4
ROBERT J DELUCCIA
29 Jul 22
4
DAVID P LUCI
29 Jul 22
4
Carl Sailer
24 Nov 21
4
ROBERT J DELUCCIA
22 Nov 21
4
DAVID P LUCI
22 Nov 21
4
Carl Sailer
10 Sep 21
SC 13D
LUCI DAVID P
6 Jul 21
SC 13D
DELUCCIA ROBERT J
6 Jul 21
4
Joseph C Scodari
6 Jul 21
4
Carl Sailer
6 Jul 21
4
THOMAS L HARRISON
6 Jul 21
4
James J. Donohue
6 Jul 21
4
JACK H DEAN
6 Jul 21
4
DAVID P LUCI
6 Jul 21
4
Robert G. Shawah
6 Jul 21
4
ROBERT J DELUCCIA
6 Jul 21
3
James J. Donohue
24 Jun 21
3
THOMAS L HARRISON
24 Jun 21
3
Joseph C Scodari
24 Jun 21
3
JACK H DEAN
24 Jun 21
3
DAVID P LUCI
24 Jun 21
3
Carl Sailer
24 Jun 21